{
    "ticker": "RLYB",
    "info": {
        "address1": "234 Church Street",
        "address2": "Suite 1020",
        "city": "New Haven",
        "state": "CT",
        "zip": "06510",
        "country": "United States",
        "phone": "203 859 3820",
        "website": "https://www.rallybio.com",
        "industry": "Biotechnology",
        "industryKey": "biotechnology",
        "industryDisp": "Biotechnology",
        "sector": "Healthcare",
        "sectorKey": "healthcare",
        "sectorDisp": "Healthcare",
        "longBusinessSummary": "Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.",
        "fullTimeEmployees": 25,
        "companyOfficers": [
            {
                "maxAge": 1,
                "name": "Dr. Martin W. MacKay Ph.D.",
                "age": 67,
                "title": "Co-Founder & Executive Chairman",
                "yearBorn": 1956,
                "fiscalYear": 2023,
                "totalPay": 723350,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Dr. Stephen  Uden M.B, M.D.",
                "age": 65,
                "title": "Co-Founder, President, CEO & Director",
                "yearBorn": 1958,
                "fiscalYear": 2023,
                "totalPay": 723350,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Mr. Jonathan I. Lieber M.B.A.",
                "age": 53,
                "title": "CFO & Treasurer",
                "yearBorn": 1970,
                "fiscalYear": 2023,
                "totalPay": 667134,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Dr. Steven W. Ryder F.A.C.P, M.D.",
                "age": 72,
                "title": "Chief Medical Officer",
                "yearBorn": 1951,
                "fiscalYear": 2023,
                "totalPay": 680219,
                "exercisedValue": 0,
                "unexercisedValue": 0
            }
        ],
        "auditRisk": 3,
        "boardRisk": 7,
        "compensationRisk": 8,
        "shareHolderRightsRisk": 5,
        "overallRisk": 6,
        "governanceEpochDate": 1730073600,
        "compensationAsOfEpochDate": 1703980800,
        "maxAge": 86400,
        "priceHint": 4,
        "previousClose": 1.02,
        "open": 1.01,
        "dayLow": 0.995,
        "dayHigh": 1.0601,
        "regularMarketPreviousClose": 1.02,
        "regularMarketOpen": 1.01,
        "regularMarketDayLow": 0.995,
        "regularMarketDayHigh": 1.0601,
        "beta": -1.697,
        "forwardPE": -0.74452555,
        "volume": 25075,
        "regularMarketVolume": 25075,
        "averageVolume": 77596,
        "averageVolume10days": 111400,
        "averageDailyVolume10Day": 111400,
        "bid": 0.9947,
        "ask": 1.07,
        "bidSize": 100,
        "askSize": 100,
        "marketCap": 42317352,
        "fiftyTwoWeekLow": 0.962,
        "fiftyTwoWeekHigh": 4.45,
        "priceToSalesTrailing12Months": 141.5296,
        "fiftyDayAverage": 1.10566,
        "twoHundredDayAverage": 1.46974,
        "currency": "USD",
        "enterpriseValue": -46012664,
        "floatShares": 18975177,
        "sharesOutstanding": 41487600,
        "sharesShort": 536633,
        "sharesShortPriorMonth": 579074,
        "sharesShortPreviousMonthDate": 1726185600,
        "dateShortInterest": 1728950400,
        "sharesPercentSharesOut": 0.0128999995,
        "heldPercentInsiders": 0.04058,
        "heldPercentInstitutions": 0.76945,
        "shortRatio": 10.09,
        "shortPercentOfFloat": 0.018099999,
        "impliedSharesOutstanding": 41487600,
        "bookValue": 1.929,
        "priceToBook": 0.52877134,
        "lastFiscalYearEnd": 1703980800,
        "nextFiscalYearEnd": 1735603200,
        "mostRecentQuarter": 1719705600,
        "netIncomeToCommon": -73881000,
        "trailingEps": -1.78,
        "forwardEps": -1.37,
        "enterpriseToRevenue": -153.889,
        "enterpriseToEbitda": 0.623,
        "52WeekChange": -0.75886524,
        "SandP52WeekChange": 0.3763833,
        "exchange": "NMS",
        "quoteType": "EQUITY",
        "symbol": "RLYB",
        "underlyingSymbol": "RLYB",
        "shortName": "Rallybio Corporation",
        "longName": "Rallybio Corporation",
        "firstTradeDateEpochUtc": 1627565400,
        "timeZoneFullName": "America/New_York",
        "timeZoneShortName": "EDT",
        "uuid": "49dd8bea-3b9a-369d-b66d-d25eaa1b0182",
        "messageBoardId": "finmb_1673028342",
        "gmtOffSetMilliseconds": -14400000,
        "currentPrice": 1.02,
        "targetHighPrice": 15.0,
        "targetLowPrice": 6.0,
        "targetMeanPrice": 10.5,
        "targetMedianPrice": 10.5,
        "recommendationMean": 2.2,
        "recommendationKey": "buy",
        "numberOfAnalystOpinions": 4,
        "totalCash": 88614000,
        "totalCashPerShare": 2.136,
        "ebitda": -73855000,
        "totalDebt": 284000,
        "quickRatio": 7.287,
        "currentRatio": 7.519,
        "totalRevenue": 299000,
        "debtToEquity": 0.355,
        "revenuePerShare": 0.007,
        "returnOnAssets": -0.38539,
        "returnOnEquity": -0.67387,
        "freeCashflow": -26663124,
        "operatingCashflow": -53991000,
        "grossMargins": 2.50502,
        "operatingMargins": -56.973244,
        "financialCurrency": "USD",
        "trailingPegRatio": null
    }
}